Issue navigation
Volume 32, Issue suppl_1, January 2017
The therapeutic portfolio for glomerular diseases: present and future opportunities
CLINICAL SCIENCE REVIEWS
Management of Glomerular Diseases
New approaches to trials in glomerulonephritis
Nephrology Dialysis Transplantation, Volume 32, Issue suppl_1, January 2017, Pages i1–i6, https://doi.org/10.1093/ndt/gfw364
Clinical trials in minimal change disease
Nephrology Dialysis Transplantation, Volume 32, Issue suppl_1, January 2017, Pages i7–i13, https://doi.org/10.1093/ndt/gfw235
What are we missing in the clinical trials of focal segmental glomerulosclerosis?
Nephrology Dialysis Transplantation, Volume 32, Issue suppl_1, January 2017, Pages i14–i21, https://doi.org/10.1093/ndt/gfw324
Membranous nephropathy: thinking through the therapeutic options
Nephrology Dialysis Transplantation, Volume 32, Issue suppl_1, January 2017, Pages i22–i29, https://doi.org/10.1093/ndt/gfw404
Is there a role for immunosuppression in immunoglobulin A nephropathy?
Nephrology Dialysis Transplantation, Volume 32, Issue suppl_1, January 2017, Pages i30–i36, https://doi.org/10.1093/ndt/gfw342
Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn
Nephrology Dialysis Transplantation, Volume 32, Issue suppl_1, January 2017, Pages i37–i47, https://doi.org/10.1093/ndt/gfw384
Managing glomerular disease in pregnancy
Nephrology Dialysis Transplantation, Volume 32, Issue suppl_1, January 2017, Pages i48–i56, https://doi.org/10.1093/ndt/gfw319
Mechanisms of Glomerular Diseases
Many drugs for many targets: novel treatments for complement-mediated glomerular disease
Nephrology Dialysis Transplantation, Volume 32, Issue suppl_1, January 2017, Pages i57–i64, https://doi.org/10.1093/ndt/gfw228
Therapeutics for APOL1 nephropathies: putting out the fire in the podocyte
Nephrology Dialysis Transplantation, Volume 32, Issue suppl_1, January 2017, Pages i65–i70, https://doi.org/10.1093/ndt/gfw402
Biomarkers of lupus nephritis histology and flare: deciphering the relevant amidst the noise
Nephrology Dialysis Transplantation, Volume 32, Issue suppl_1, January 2017, Pages i71–i79, https://doi.org/10.1093/ndt/gfw300
Is there a role for TNFα blockade in ANCA-associated vasculitis and glomerulonephritis?
Nephrology Dialysis Transplantation, Volume 32, Issue suppl_1, January 2017, Pages i80–i88, https://doi.org/10.1093/ndt/gfw361
What can target kidney fibrosis?
Nephrology Dialysis Transplantation, Volume 32, Issue suppl_1, January 2017, Pages i89–i97, https://doi.org/10.1093/ndt/gfw388
ORIGINAL ARTICLES
Learning to live with nephrotic syndrome: experiences of adult patients and parents of children with nephrotic syndrome
Nephrology Dialysis Transplantation, Volume 32, Issue suppl_1, January 2017, Pages i98–i105, https://doi.org/10.1093/ndt/gfw344
Provider perspectives on treatment decision-making in nephrotic syndrome
Nephrology Dialysis Transplantation, Volume 32, Issue suppl_1, January 2017, Pages i106–i114, https://doi.org/10.1093/ndt/gfw309
Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome
Nephrology Dialysis Transplantation, Volume 32, Issue suppl_1, January 2017, Pages i115–i122, https://doi.org/10.1093/ndt/gfw353
Mycophenolate mofetil therapy in immunoglobulin A nephropathy: histological changes after treatment
Nephrology Dialysis Transplantation, Volume 32, Issue suppl_1, January 2017, Pages i123–i128, https://doi.org/10.1093/ndt/gfw326
Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond
Nephrology Dialysis Transplantation, Volume 32, Issue suppl_1, January 2017, Pages i129–i138, https://doi.org/10.1093/ndt/gfw336
Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis
Nephrology Dialysis Transplantation, Volume 32, Issue suppl_1, January 2017, Pages i139–i145, https://doi.org/10.1093/ndt/gfw299
Copeptin, a surrogate marker for arginine vasopressin, is associated with disease severity and progression in IgA nephropathy patients
Nephrology Dialysis Transplantation, Volume 32, Issue suppl_1, January 2017, Pages i146–i153, https://doi.org/10.1093/ndt/gfw391
